Parkinson's disease is associated with gastrointestinal tract dysfunction, where constipation is reported 25 as the most common gastrointestinal symptom. Aromatic bacterial metabolites are attracting 26 considerable attention due to their implication on gut homeostasis and host's physiology. Clostridium 27 sporogenes is a key contributor to the production of these bioactive metabolites in the human gut. Here, 28
Introduction 38
Gut bacteria produce a wide range of small bioactive molecules from different chemical classes, 39
including aromatic amino acids (Donia and Fischbach, 2015) . Bacterial products from aromatic amino 40 acid degradation have been shown to play a critical role in intestinal barrier function, immune 41 modulation and gut motility (Bansal et al., 2010; Bhattarai et al., 2018; Schiering et al., 2017; Venkatesh 42 et al., 2014; Yano et al., 2015) . In the lower part of the gastrointestinal tract, where oxygen is limited, 43 aromatic amino acid degradation by anaerobic bacteria involves reductive or oxidative deamination 44 (Barker, 1981) resulting in production of aromatic metabolites (Dodd et al., 2017; Elsden et al., 1976; 45 Nierop Groot and De Bont, 1998; Yvon et al., 1997) . Among these metabolites is 3-indolepropionic acid 46 (IPA), which is produced from tryptophan deamination by Clostridium sporogenes (Hoogerheide and 47 Kocholaty, 1938) , via tryptophan transaminase (O'Neil and DeMoss, 1968) and indolelactate 48 dehydrogenase (Jean and DeMoss, 1968). We hypothesized that the non-proteinogenic amino acid and 49 the main treatment of Parkinson's disease (PD), levodopa, could also be deaminated by the gut 50 bacterium C. sporogenes. More recently, the enzymes involved in the deamination pathway of the 51 aromatic amino acids tryptophan, phenylalanine and tyrosine were described (Dickert et al., 2000 (Dickert et al., , 2002 52 Dodd et al., 2017) . However, the enzyme involved in the initial transamination step remains unknown. 53 Figure 1c ). To further investigate the involvement of the deaminase pathway in levodopa and 5-HTP 92 deamination, the enzyme responsible for the dehydratase reaction (encoded by the fldC gene) was 93 disrupted using the ClosTron mutagenesis system (Supplementary Figure 2a) (Heap et al., 2010) . The 94 resulting strain C. sporogenes Ll.LtrB-ery R ΩfldC (CS ΩfldC ) was incubated with levodopa, revealing that 95 levodopa was no longer deaminated to DHPPA but to its intermediate product 3-(3,4-96 dihydroxyphenyl)lactic acid (DHPLA) (Figure 1b) . Tryptophan and tyrosine are converted to their 97
intermediates ILA (indole-3-lactic acid) and 4HPLA (3-(4-hydroxyphenyl)lactic acid), respectively. 98
Only a slight production of 4HPPA (from tyrosine) is observed after 48 h, potentially because of the 99 substitution of FldABC by the similar HadABC proteins from the had-operon in C. sporogenes (Dickert 100 et al., 2002; Dodd et al., 2017) . HPLC-ED analysis of the 5HILA production from 5-HTP by the fldC 101 mutant was hampered by the production of coeluting 3-(4-hydroxyphenyl) lactic acid (4HPLA), a 102 metabolic intermediate deamination product produced from tyrosine. However, the analysis revealed 103 that the second unknown peak produced from 5-HTP was no longer produced by CS ΩfldC (Figure 1b) , 104 demonstrating that 5-HTP conversion is affected and suggesting that the unknown product is 5-105 hydroxyindole-3-propionic acid (5HIPA). Overall, these results show that the deamination pathway 106 from C. sporogenes is not only involved in the deamination of PAAAs but also is important in the 107 deamination of NPAAAs like 5HTP and levodopa. 108 disrupted (resulting in CS ΩCLOSPO_01732 (Supplementary Figure 2a) ) and a targeted metabolomic 118 analysis of all the (N)PAAA metabolites was performed using HPLC-ED (except metabolites from 119 phenylalanine, which were quantified using HPLC-UV). Comparing the metabolic profiles from wild 120 type C. sporogenes (CS WT ), CS ΩfldC and CS ΩCLOSPO_01732 demonstrated that none of the other tested 121 aminotransferases could take over this transaminase reaction effectively, except for the substrate 122 phenylalanine (Figure 2b and Supplementary Table 1 ). Disrupting CLOSPO_01732 reduced the 123 production of phenyl-3-propionic acid (PPA), 3-(4-hydroxyphenyl)propionic acid (4HPPA), IPA, and 124 DHPPA by 16.4%, 79.0%, 97.2%, 97.7% respectively compared to CS WT within 24 h. Presumably, the 125 transamination of phenylalanine is substituted by EDU37030 as this aminotransferase also showed 126 significant phenylalanine-converting activity in vitro (Figure 2a ). Interestingly, CS ΩCLOSPO_01732 127 produces significantly higher amounts of tryptamine (4 to 6-fold increase at 24 and 48 h, respectively) 128 compared to CS WT (p≤0.0001), reflecting a reduced competition for the same substrate by different 129 enzymes. Analogous to tryptamine, CS ΩCLOSPO_01732 produced significantly more serotonin compared to 130 CS WT at 48 h (p<0.0001) when incubated with 5-HTP (Figure 2b, Supplementary Figure 2c , 131 7 acetylcholine induced contractility in the ileum. Acetylcholine, produced from the excitatory circular 145 muscle motor neurons, is the neurotransmitter directly acting on gut smooth muscle contractility (Costa 146 et al., 2000) . After 5 min, induction of an acetylcholinergic twitch by adding 50 µM of acetylcholine, 147 DHPPA (100 µM) specifically inhibited the amplitude (measured as the standard deviation of the mean), 148
but not the frequency of the acetylcholinergic twitch after 15 min (Figure 3a,b) . When incubation times 149 were binned in intervals of 5 min a significant decrease (up to 60% reduction) in the acetylcholinergic 150 twitch by DHPPA was observed at the 10-15-and 15-20-min interval (Figure 3c) , showing that DHPPA 151 can inhibit the acetylcholinergic twitch of mouse ileum ex vivo. 152
Higher DHPPA concentrations in fecal samples from PD patients compared to healthy controls 153
Although levodopa is mainly absorbed in the proximal small intestine, a significant amount reaches the 154 distal part of the intestinal tract (Morgan, 1971) , and these levels increase with age (Iwamoto et al., 155 1987). Thus, we hypothesized that PD patients have considerable amounts of DHPPA in their distal GI-156 tract if C. sporogenes or other bacteria with such a pathway (Peptostreptococcus anaerobius or 5a). For other samples, DHPPA detection was hampered by interference of other unknown peaks present 172 in the sample. Therefore the same samples were re-injected using a lower voltage on the ED (0.8 V) 173 making the detection more selective for more readily oxidizable compounds (Nagatsu and Kojima, 174 1988) such as DHPPA, but making 3HPPA invisible for detection. Using the lower voltage resulted in 175 the detection of DHPPA in 35% of all samples (Supplementary Figure 3) . Because DHPPA is further 176 converted to 3HPPA in vitro (Supplementary Figure 3) , we quantified the production of 3HPPA in the 177 fecal incubations as measure for deamination. In 60% and 40% of PD and HC respectively, 3HPPA 178 production was observed within 45 h (Figure 5b, Supplementary Figure 3) . 179
Eggerthella lenta has been shown to be able to perform p-dehydroxylation of the catecholic B-ring from 180 (+)-catechin and (-)-epicatechin (Jin and Hattori, 2012), a moiety resembling DHPPA. To test whether 181 E. lenta could produce 3HPPA from the dihydroxylation of DHPPA, E. lenta DSM 2243 was grown at 182 various concentrations of arginine, which was previously shown to improve growth densities (Haiser et 183 al., 2013) . At low arginine concentrations, E. lenta DSM2243 was capable of dehydroxylation of 184 DHPPA to 3HPPA, which was inhibited at higher arginine concentrations (Figure 5c) . 185
Taken together, the results show that DHPPA can be produced by the microbiota via anaerobic 186 deamination of levodopa. Moreover, our findings indicate that 3HPPA originates from DHPPA via 187 dehydroxylation potentially by Eggerthella lenta and that the aromatic deamination pathway, as 188 measured by the production of 3HPPA, is active in at least 50% of the PD and HC samples. 189
Discussion and Conclusion 190
Identifying bacterial pathways and elucidating their potential impact on bacterial drug metabolism is 191 crucial in order, not only, to maximize medication efficacy, but also to recognize and eventually prevent 192 reductive anaerobic deamination pathway in C. sporogenes by identifying its initiating enzyme, the convert two clinically important NPAAAs, levodopa and 5-HTP. We showed that C. sporogenes is able 197 to completely deaminate levodopa to DHPPA and to a much lesser extent 5-HTP (Figures 1, 2) . 198
Disrupting the bacterial transaminase encoding gene abolished the production of deaminated products, 199 and increased the production of neuromodulators such as tryptamine and, to much lesser extent, 200 serotonin (Figure 2, Supplementary Figure 2c and Supplementary Table 1 ). Tryptamine is a natural 201 product produced by C. sporogenes that has been proposed to modulate gut transit time (Williams et al., 202 2014) . The application of engineered gut bacteria as a therapeutic strategy to modulate GI-motility or 203 host physiology has been also proposed recently in two proof-of-concept studies; by heterologous shown to inhibit methacholine (analog of acetylcholine) induced contraction, which is not mediated via 220 dopamine receptors, in guinea pig jejunum in similar concentration ranges to DHPPA (EC50 relaxation 221 by dopamine ~290 µM) (Lucchelli et al., 1990) , indicating that DHPPA might act on a similar receptor.
DHPPA inhibits the acetylcholine-induced muscle contractions in the ileum with implications on 224
intestinal motility, often observed in PD patients. Overall, the present study highlights the urgency to 225 unravel potential effects of gut bacterial processing of (unabsorbed residues of) medication, such as 226 levodopa. to be involved in all transaminase reactions. EDU37030 showed similar activity as EDU38870, for 252 phenylalanine. (B) Targeted metabolic quantification of deamination products from CS WT , CS ΩfldC , 253 CS ΩCLOSPO_01732 reveals that EDU38870 is involved in the transamination of all for all tested (N)PAAAs. 254
All quantified deamination products are normalized to their initial substrate concentration and the data 255 represents 3 independent experiments. Black squares indicate that quantification was not possible 256 because of an interfering HPLC-ED peak. As no commercial standards are available for 5HILA and 257 5HIPA, the peaks were quantified assuming a similar ED-detector response as for 5HTP. Corresponding 258 values are given in Supplementary Table 2 . Significance was tested when relevant (see p-values in text) 259 using 2-way ANOVA followed by a Tukey test. 
Growth and incubation of Clostridium sporogenes and Eggerthella lenta 332
Clostridium sporogenes ATCC15579 was grown in enriched beef broth (EBB) with 2 g/L glucose (van 
Protein production and purification 345
Transaminase-encoding genes from C. sporogenes ( Supplementary Table 3 ) were amplified using 346
Phusion High-fidelity DNA polymerase and primers listed in Supplementary Table 3 . All amplified 347 genes were cloned in pET15b, except for EDU37032 which was cloned in pET28b (Supplementary 348 Cell debris was removed by centrifugation at 20,000 × g for 20 min at 4 °C. The 6 × his-tagged proteins 359 were purified using a nickel-nitrilotriacetic acid (Ni-NTA) agarose matrix (30250, Qiagen). Cell-free 360 extracts were loaded on 0.5 ml Ni-NTA matrixes and incubated on a roller shaker for 2 h at 4 °C. The 361
Ni-NTA matrix was washed three times with 1.5 mL buffer B (300 mM NaCl; 20 mM imidazole; 50 362 mM KPO4, pH 8.0) before elution with buffer C (300 mM NaCl; 250 mM imidazole; 50 mM KPO4, 363 pH 8.0). Imidazole was removed from purified protein fractions using Amicon Ultra centrifugal filters 364 (UFC505024, Merck) and washed three times and reconstituted in buffer D (50 mM Tris-HCl; 30 0mM 365 NaCl; pH 7.5). Protein concentrations were measured spectrophotometrically (Nanodrop 2000, Isogen, 366
De Meern, The Netherlands) using the predicted extinction coefficient and molecular weight from 367
ExPASy ProtParam tool (www.web.expasy.org/protparam/). 368
Transaminase activity test 369
Purified transaminases were incubated with 1 mM substrate, 2 mM α-ketoglutaric acid, and 0.1 mM 370 PLP (pyridoxal-5-phosphate, P9255, Sigma, The Netherlands) in buffer D with an enzyme concentration 371 of 50 nM for tyrosine, tryptophan, or 5-HTP as substrate and an enzyme concentration of 500 nM for 372 phenylalanine and levodopa as substrate. Enzyme reactions were incubated for 0.5 h at 37 °C, the 373 reactions were stopped with 0.7% (v/v) perchloric acid (1:1). Transaminase activity was tested using an 374 L-glutamic acid detection kit (K-GLUT, Megazyme Inc., Wicklow, Ireland), according to the 375 manufacture's microplate assay procedure with some modifications. The supplied buffer was substituted 376 for buffer D (described above, to prevent oxidation of the substrates/products). A reaction mix was 377 prepared mixing 50 µL buffer D; 10 µL quenched sample reaction mixture, 20 µL 378 NAD + /iodonitrotetrazolium chloride solution, 5 µL diaphorase solution, 5 μL glutamate dehydrogenase 379 (GIDH) solution and reconstituted to a final volume of 290 µL with H2O. Absorbance at 492 nm was 380 measured after 10 minutes of incubation using a microplate reader (Synergy HTX spectrophotometer, Gene disruptions in Clostridum sporogenes were performed using the ClosTron system (Heap et al., 385 2007 (Heap et al., 385 , 2009 ). This system facilitates targeted mutagenesis using the group-II Ll.LtrB intron of 386 Lactococcus lactis. Introns targeting fldC (CLOSPO_311) or CLOSPO_1732 (encoding for the 387 transaminase) were designed using the ClosTron intron design tool (http://www.clostron.com) and were 388 ordered in pMTL007C-E2 from ATUM (Newark, California, United States) resulting in pMTL007C-389
E2_Cs-fldC-561a and pMTL007C-E2_Cs-CLOSPO_1732-493s respectively. Plasmids were 390 transferred to C. sporogenes by conjugation as described before (Heap et al., 2009) Sequentially, 1 mL of PBS was added to the spotted plates and the donor-recipient mix was scraped of 399 the plate, sequentially the scraped-off suspension was distributed over TSA plates containing 50 µg/mL 400 neomycin (to prevent growth of E. coli) and 15 µg/mL chloramphenicol to select for C. sporogenes 401 conjugants. Chloramphenicol resistant colonies of C. sporogenes were re-streaked on TSA plates 402 containing 50 µg/mL neomycin and 2.5 µg/mL erythromycin (to select for intron insertion) for several 403 times. To makes sure the plasmids was integrated, colonies were checked and selected for their 404 sensitivity towards chloramphenicol and the genomic DNA was verified using PCR (Supplementary 405
Figure 2a) 406

Fecal samples from patients with Parkinson's disease and age-matched healthy controls 407
Fecal samples from patients diagnosed with PD (n = 10) and age-matched healthy controls (n = 10) were 408 acquired from the Movement Disorder Center at Rush University Medical Center, Chicago, Illinois, samples for research. PD was diagnosed according to the UK Brain Bank Criteria as previously 411 described (Keshavarzian et al., 2015) . Study subjects were provided with the supplies and instructions 412 for home feces collection using the BD Gaspak EZ Anaerobe Gas Generating Pouch System with 413 Indicator (Ref 260683; Becton, Dickinson and Company, Sparks, MD) in order to minimize the 414 exposure of the feces to high oxygen ambient atmosphere, which may alter the microbiota. Subjects 415 were asked to have a bowel movement within 24 h of their study visit. Subjects kept the sealed anaerobic 416 fecal bag in a cold environment, before bringing the anaerobic fecal bag to the hospital. Fecal samples 417 were then immediately stored at -80°C until analysis. 418 419
Fecal metabolite incubations from PD patients and HC subjects 420
Stool samples were suspended 1:1 (w/v) in EBB/T and incubated anaerobically (10% H2, 10% CO2, 421 80% N2) in a Don Whitley Scientific DG250 Workstation (LA Biosystems, Waalwijk, The Netherlands) 422 at 37 °C with 100 µM Sodium 3-(3,4-dihydroxyphenyl)-DL-lactate (39363,Sigma). Samples were taken 423 at 0, 20, and 45 h and analyzed on HPLC-ED as described below. 424 425
HPLC-ED/UV analysis and sample preparation 426
For bacterial cell suspensions, 1 mL of methanol was added to 0.25 mL of cell suspension and stored at 427 -20 °C until further use. For fecal metabolite incubations, 300 µl of methanol was added to 75 µL of 428 fecal suspension and stored at -20°C until further use. Metabolites from stool samples were extracted by 429 suspending the stool 1:1 (w/v) in water, followed by homogenization by vigorously vortexing while 430 keeping samples as cold as possible. Homogenized suspensions were centrifuged at 3500 × g for 20 min 431 at 4°C and sequentially 1.6 mL of methanol was added to 0.4 mL of supernatant. From bacterial, fecal 432 incubation or stool samples cells and protein precipitates were removed by centrifugation at 20000 × g 433 for 10 min at 4°C. Supernatant was transferred to a new tube and the methanol fraction was evaporated 434 in a Savant speed-vacuum dryer (SPD131, Fisher Scientific, Landsmeer, The Netherlands) at 60°C for 435 1.5-2 h. The aqueous fraction was reconstituted with 0.7% HClO4 to the appropriate volume. Samples 436 were filtered and injected into the HPLC-ED system (Alliance Separations Module 2695, Waters Ag/AgCl as reference electrode)). Samples were analyzed on a C18 column (Kinetex 5µM, C18 100 Å, 440 250 × 4.6 mm, Phenomenex, Utrecht, The Netherlands) using a gradient of water/methanol with 0.1% 441 formic acid (0-10 min, 95−80% H2O; 10-20 min, 80-5% H2O; 20-23 min 5% H2O; 23-31 min 95% 442 H2O). For the detection of the C. sporogenes metabolites and for peak isolation another HPLC-ED 443 system was used (Jasco AS2059 plus autosampler, Jasco Benelux, Utrecht, The Netherlands; Knauer K-444 1001 pump, Separations, H. I. Ambacht, The Netherlands) with the same detector (ED40) and the same 445 gradient as described above. Phenylalanine metabolites were detected by injecting the same samples in 446 an HPLC-UV system (Alliance Separations Module 2695, Waters Chromatography B.V, Etten-Leur, 447
The Netherlands; TSP UV6000LP UV-detector (wavelength: 260 nM) Thermo Scientific, The 448 Netherlands). Samples for peak isolation were separated on a Vydac Semi-preparative C18 column 449 (218TP510, 5 µm, 300 Å, 10 mm × 250 mm, VWR International B.V, Amsterdam, The Netherlands) at 450 3 ml/min using the same gradient as above. Data recording and analysis was performed using 451
Chromeleon software (version 6.8 SR13). 452 453 Catechol extraction from stool for DHPPA quantification 454 Catechols were extracted from PD patients and HC stool samples using activated alumina powder 455 (199966, Sigma) as previously described (van Kessel et al., 2019) with a few modifications. A volume 456 of 200 μl 50% stool suspension (described above) was used with 1 mM DHBA (3,4-457 dihydroxybenzylamine hydrobromide, 858781, Sigma) as an internal standard. Samples were adjusted 458 to pH 8.6 with 800 μL TE buffer (2.5% EDTA; 1.5 M Tris/HCl pH 8.6) and 5-10 mg of alumina was 459 added. Suspensions were mixed on a roller shaker at room temperature for 20 min and were sequentially 460 centrifuged for 30 s at 20,000× g and washed three times with 1 mL of H2O by aspiration. Catechols 461 were eluted using 0.7% HClO4 and filtered before injection into the HPLC-ED-system as described 462 above (DC amperometry at 0.8 V). A standard curve was injected to quantify the concentrations of
LC-MS 466
HPLC-MS analysis was performed using an Accella1250 HPLC system coupled with the benchtop ESI-467 MS Orbitrap Exactive (Thermo Fisher Scientific, San Jose, CA, USA) in negative and positive ion mode. 468
Samples were analyzed on a C18 column (Shim Pack Shimadzu XR-ODS 3 × 75 mm) using a gradient 469 of water/acetonitrile with 0.1% formic acid (0-5 min, 98−90% H2O; 5-10 min, 90-5% H2O; 10-13 min 470 5% H2O; 13-14 min 98% H2O). Data analysis was performed using Qual Browser Thermo Xcalibur 471 software (version 2.2 SP1.48). Samples were analyzed on a C18 column (Shim Pack Shimadzu XR-ODS 3 × 75 mm) using a gradient 477 of water/acetonitrile with 0.1% formic acid (0-5 min, 98−90% H2O; 5-10 min, 90-5% H2O; 10-13 min 478 5% H2O; 13-15 min 2% H2O; 15-17 min 98% H2O). Data analysis was performed using Bruker Compass 479 Data Analysis (version 4.2 SR1). 480
NMR 482
Samples were exchanged once with 99.9 atom% D2O with intermediate lyophilization, finally dissolved 483 in 650 µL D2O. One-dimensional 1 H NMR was recorded at a probe temperature of 25°C on a Varian 484 Inova 500 spectrometer (NMR Department, University of Groningen). 1 H chemical shifts are expressed 485 in ppm in reference to external acetone (δ 1 H 2.225). 1D 500-MHz 1 H NMR spectra were recorded with 486 5000 Hz spectral width at 16 k complex data points, using a WET1D pulse to suppress the HOD signal. 487 Spectra were processed using MestReNova v9.1 (Mestrelabs Research SL, Santiago de Compostela,
